Many seminal discoveries in molecular biology have their origin in seeking differences between one functional state of a biological system versus another. Ubiquitination, for example, was first discovered by comparing stressed cells with cells under normal conditions. Knowledge of growth factor signaling owes much to comparing cells transformed with Rous sarcoma virus with their normal counterparts. Such discoveries have necessarily involved a great deal of luck as they relied on finding the critical difference in the part of the system that we are able to measure, hence the attraction of comprehensive or system-wide analyses.
Differences between cellular states are reflected in changes in gene expression that manifest themselves at the level of both the message (mRNA) and the final product (protein). The first "genome-wide" method for expression analysis was the largescale hybridization of mRNA to complementary sequences immobilized on chips. As each possible message can be placed on the chip at a known location, microarrays can in principle cover the whole transcriptome. Despite their ubiquity and tremendous usefulness, microarrays have certain limitations. These are partly technology related; for example, issues with reproducibility across platforms and laboratories have not been fully resolved (Canales et al., 2006) . More important is the nonquantitative nature of the microarray measurements in predicting the amount of change in the active mature protein. Proteins are almost always the effectors of biological functions, but protein levels depend not only on the levels of the corresponding messages but also on a host of translational controls and regulated degradation (Gygi et al., 1999b; Lu et al., 2007) . These factors may be just as important as increased synthesis of mRNA and they cannot be measured directly by microarrays.
The expression levels of all proteins would arguably provide the most relevant single data set characterizing a biological system. Thus the idea of "proteomics," which aims to provide just that, has had strong appeal even before the term was coined a decade ago. From the mid 1970s, proteomics was pursued with two-dimensional gel electrophoresis, but unfortunately that technology never fully delivered on its promise. Biological mass spectrometry (MS), the technological basis of most current proteomics studies, was first catapulted to mainstream prominence with the development of the electrospray and MALDI ionization techniques. This advance made biological molecules readily amenable to mass spectrometry and garnered the Chemistry Nobel Prize in 2002. A number of decisive breakthroughs followed, including protocols to handle small amounts of biological samples, the ability to rapidly identify peptides by matching their MS fragmentation spectra to sequence databases, and the direct analysis of very complex protein mixtures (Aebersold and Mann, 2003; Yates et al., 2005) . Most recently, high performance but robust MS instruments have further increased the power of MS-based proteomics at a furious clip. Mass spectrometry has also become a powerful tool for detecting posttranslational modifications and protein interactions.
Meanwhile, progress on quantitative methods has been slower. As MS is not inherently quantitative, samples are labeled with stable isotopes. Labeling can be performed chemically by reacting the sample with light or heavy versions of an isotope tag, as in the original ICAT (Gygi et al., 1999a) or the popular iTRAQ methods (Ross et al., 2004) . Alternatively, whole proteomes can be labeled metabolically (Oda et al., 1999; Ong et al., 2002) , or isotopically labeled peptides can be spiked into the proteome to enable quantitation of specifically targeted peptides (Aebersold, 2003; Gerber et al., 2003) . Despite these and other ingenious approaches (reviewed in Ong and Mann, 2005) , only limited proteomes have been quantified so far. Recently, a number of technological and methodological developments have combined to change this picture, and here we argue that MS-based proteomics is finally ready for systems-wide measurement of protein expression levels. If so, many of the powerful systems-wide approaches previously restricted to the mRNA level could now be performed directly at the protein level. Thus, we argue that proteomics could become the "new genomics."
Challenges of Proteome-wide Expression Analysis Despite remarkable progress using MS to investigate biological problems, the challenges of proteomics are daunting. Unlike oligonucleotides, proteins cannot be amplified and therefore sensitivity is of the essence. In order to make proteins amenable to MS analysis, they first need to be digested to peptides. However, this (Kuster et al., 2005) . As a result of these and other limitations, some authorities have questioned the capability of MSbased "shotgun" proteomics to ever arrive at a comprehensive coverage of any proteome using currently established methodology (Domon and Aebersold, 2006; Nielsen et al., 2006) . Adding to the challenge, it is not only identification of proteins that is needed but also comprehensive quantitation of protein levels in cells.
Quantifying the Proteome
To address the quantitation problem, we have used a stable isotope-based technique termed stable isotope labeling by amino acids in cell culture or SILAC (Ong et al., 2002) . Using the SILAC method, cells are metabolically labeled by either normal ("light") or "heavy" isotope versions of an essential stable (i.e., nonradioactive) amino acid, thus enabling the proteomes to be distinguished by MS. Each instance of the amino acid is labeled in the two proteomes and therefore each peptide appears in two forms separated on the massto-charge scale by the difference between light and heavy label, for instance six 13 C carbon atoms versus six 12 C carbon atoms. The ratio in peak heights between the two forms corresponds directly to the difference in protein amount between the two cell states.
Using SILAC technology, we analyzed the factors preventing complete proteome quantitation in yeast, which is the only organism to have a reasonably well-defined proteome (Ghaemmaghami et al., 2003) . Interestingly, we found that raw mass spectrometric sensitivity was already adequate for full proteome analysis using modern instrumentation (de Godoy et al., 2006) . However, there are two other parameters limiting the analysis and preventing full proteome identification. First, the instrument has a finite peptide sequencing speed and only managed to target one third of eluting peptides for fragmentation. This problem could be readily addressed using more intelligent acquisition software to avoid repeatedly re-measuring the same or closely related peptides. The other limitation is the dynamic range of measurement, that is, the lowest abundant peptides that can be measured by the mass spectrometer in the presence of the highest abundance peptides. We estimated that sufficient dynamic range could be achieved by sample fractionation in combination with changes in MS instrumentation. Figure 1 shows an example of using the SILAC technology on a mammalian cellular proteome. HeLa cells were labeled with two different amino acid forms (light and heavy) to directly compare two cellular states ( Figure  1A ). We detected a total of 239,848 SILAC peptide doublets and identified 24,230 nonredundant peptide sequences corresponding to 4,034 quantifiable proteins in the HeLa cell proteome (see Supplemental Data available with this article online). This demonstrates that modern proteomic methods can now quantify a substantial part of a cellular proteome.
Another interesting aspect of the experiment is illustrated in Figure  1D where the protein ratios are plotted as a function of abundance and fold change between the light and heavy SILAC states. The vast majority of protein ratios are below two, which represents excellent quantitative accuracy of gene expression in a large-scale experiment.
Proteomics and Transcriptomics Are Equally Comprehensive
To compare the current state of coverage of MS-based proteomics to that obtained with microarray expression analysis, we analyzed a published data set using Affymetrix microarray measurement of gene expression in HeLa cells (Carson et al., 2004) . A comparison of this microarray data set with the proteomic HeLa data set mentioned above is shown in Figure 2A . A large overlap between MS data and Affymetrix data is evident, but a substantial number were only detected as either message or protein. Part of the latter population is owing to the fact that 668 genes corresponding to proteins identified in the International Protein Index (IPI) database were not represented on the chip. Of the total 7,278 genes unambiguously detected either as message or protein, MS-based proteomics quantified 55% and the microarray 77%. This shows that both methods provide reasonably comprehensive "system-wide" measures of gene expression.
Depending on the source of cells, proteomics rather than microarray analysis may be a better investigational tool. For example, certain tissues and body fluids such as blood do not contain representative mRNA populations and are better suited to proteomics analysis. Figure 2B illustrates the feasibility of quantifying such tissues by "label-free" proteomics. Label-free proteomics refers to the absence of an isotopic label and to the fact that quantitation is performed by directly comparing MS measurements of the different samples. Unlike stable isotope-based technologies, labelfree proteomics does not control for variations in the sample work up and the samples are analyzed separately. Therefore, the resulting quantitation is generally less accurate. In this example, proteins in brain tissue samples from two individuals were extracted and analyzed separately by MS. Peptides were quantified against each other by comparing their total mass spectrometric response over the elution peak. The panel summarizes quantitation of several thousand proteins. The ratio of most proteins is almost 1:1, with relatively good quantitation achieved for the higher intensity signals. While not as accurate as SILAC-based quantitation, performance is roughly similar to the quantitative accuracy achieved at the message level in standard microarray experiments.
Perspectives
Although there are many remaining technological challenges for proteomics, the state of the technology now allows reasonably comprehensive quantitation of cellular proteomes. When stable isotopes are used, quantitation can be very accurate in these large-scale experiments, a significant development given that this has been the aspiration of proteomics for several decades. To be sure, proteomics still lags years behind microarray technology in several aspects. For example, microarray measurements are currently faster and, because of amplification, require less starting material than proteomics analyses. Furthermore, microarray facilities are more accessible than high-end proteomics laboratories. However, very advanced MS instrumentation will soon be available in hundreds of laboratories and measurement times for comprehensive proteome analysis will shrink dramatically in the near future.
It is instructive to recall how rapidly MS-based proteomics has developed over the past decade. Ten years ago, the sequencing of a single protein at very high sensitivity was a major undertaking. Today, the identification of hundreds of proteins in a single experiment is almost taken for granted. We proj- ect that technological capabilities in this field will continue to at least double every year for the foreseeable future: a Moore's law for proteomics. Furthermore, as pointed out by others, proteomics will shift from a "discovery" to a "re-measurement" mode, as most proteins and peptides are measured and deposited in databases (Kuster et al., 2005) . This will lead to increasingly comprehensive but also faster and more accessible whole-proteome quantitation.
There are already compelling reasons to consider proteomics as a complement or alternative to mRNA-based measurements. First, in areas in which microarray measurement is not feasible, proteomics is becoming a viable alternative to determine gene expression on a large scale. Blood and other body fluids are prime examples because proteins of interest are mainly extracellular and mRNA measurements are not directly relevant. Second, measuring actual protein levels, instead of using message levels as a proxy, is highly attractive in spite of the added experimental complexity. The proteomic measurement already delivers the desired end point, namely the protein expression level of a gene of interest. In contrast, a change observed on a microarray may need to be followed up by RT-PCR and western blotting experiments to determine if the observed change carries through to the protein level. In an ideal (not resource constrained) world both microarray and proteomic measurements would be performed, which would have the further advantage of directly differentiating those changes that are due to increased transcription from those that are due to alterations in translation or protein stability.
An additional reason why we believe proteomics will become the "new genomics" is that it is not limited to expression profiling of the whole cell. Cellular compartments and organelles and their time-resolved dynamics are readily accessible to this technology. First generation proteomic maps of the substructures of the cell already exist and they can be "overlaid" onto genomic data sets, in effect giving them subcellular resolution. Moreover, the classical approaches for studying cellular dynamics are all fluorescence and microscopy based. As shown recently with the nucleolus as a model system, these methods can be combined with quantitative and time-resolved proteomics to bring the power of these high-throughput methods to cell biology (Andersen et al., 2005) .
Another area that is accessible to proteomics but not to genomics is the large-scale measurement of protein modifications and their quantitative changes upon perturbations to the cell. Often these are just as important for protein activity as protein expression levels. SILAC-or iTRAQ-based quantitative proteomics is capable of determining posttranslational modifications in complex proteomes, especially if modified peptides can be biochemically enriched. For example, site-specific and time-resolved changes in phosphorylation upon growth factor stimulation in a "phosphoproteome" of more than 6000 sites have been measured . Thus, proteomics can determine the cellular response to any perturbation at the level of protein activation, such as phosphorylation, and it can determine the downstream consequences in terms of gene expression changes. Such data will give us unprecedented insight into how cells make decisions and it will likely serve as a cornerstone of systems biology.
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